Biostax (BTAX) 10-Q2022 Q1 Quarterly report

Filed: 3 May 22, 4:20pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	8th grade Avg

New words: accelerated, alleging, Aloma, Arizona, Ave, breach, chapter, check, complaint, counsel, County, Court, defendant, electronically, entry, failure, favor, filer, FL, Identification, impairment, impossible, inactive, Interactive, IRS, issuer, judgment, jurisdiction, large, lawsuit, Maricopa, mark, Mine, par, Park, penalty, plaintiff, post, posted, preceding, Qualitative, Quantitative, relief, respond, shell, shorter, site, smaller, sought, Statera, Suite, Superior, Washington, web, Winter

Removed: active, addressed, aggregate, agreed, amortization, animal, assign, assume, assumption, Authority, bifurcation, classified, clear, commercialize, conditional, consent, consisting, consulting, conversion, convert, converted, corroborated, country, deconsolidated, defaulted, designation, detailed, device, discount, documentation, earned, embedded, emerging, equaling, exclusive, execute, failed, feature, Fee, finalized, FINRA, flow, focused, formalized, Forte, Foundation, freestanding, fully, granted, headcount, Health, hierarchy, host, identical, incubate, individual, Initial, LDN, letter, licensed, Lodonal, longer, lowest, lt, mature, maturing, maximize, measure, measuring, MENK, minimize, mutually, negotiated, noteholder, notice, observable, occurrence, option, originally, pay, payroll, perpetuity, pharmaceutical, previously, prior, reaching, redemption, remaining, reversed, royalty, Schedule, sublicense, sublicensed, sublicensing, substantially, supported, technology, term, transaction, transfer, unobservable, validity, veterinary

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

BTAX similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. Section 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of Immune Therapeutics, Inc. (the “Company”) on Form 10-Q for the quarter ending March 31, 2022 as filed with the Securities and Exchange Commission (the “Report”), I , Kevin J. Phelps, Chief Executive Officer (Principal Executive Officer) and Chief Financial Officer (Principal Financial and Accounting Officer) of the Company, hereby certify as of the date hereof, solely for purposes of Title 18, Chapter 63, Section 1350 of the United States Code, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2020, that to the best of my knowledge:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.

Date: May 3, 2022	By:	/s/ Kevin J. Phelps
		Kevin J. Phelps
		Chief Executive Officer
		(Principal Executive Officer) and Chief Financial Officer (Principal Financial and Accounting Officer)

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.